Biotinylated Anti-Human sTRAIL/Apo2L 0 ReviewsSubmit a Review Product Details Catalogue Number: 500-P135BT Description: Source: Polyclonal Rabbit Preparation: Produced from sera of rabbits immunized with highly pure Recombinant Human sTRAIL/Apo2L. Anti-Human sTRAIL/Apo2L-specific antibody was purified by affinity chromatography and then biotinylated. Immunogen: E.coli-derived, 19.6 kDa Recombinant Human sTRAIL/Apo2L (PeproTech catalog# 310-04) Sandwich ELISA: To detect Human sTRAIL/Apo2L by sandwich ELISA (using 100 μl/well antibody solution) a concentration of 0.25 – 1.0 μg/ml of this antibody is required. This biotinylated polyclonal antibody, in conjunction with PeproTech’s Polyclonal Anti-Human sTRAIL/Apo2L (500-P135) as a capture antibody, allows the detection of at least 0.2 – 0.4 ng/well of recombinant Human sTRAIL/Apo2L. Western Blot: To detect Human sTRAIL/Apo2L by Western Blot analysis this antibody can be used at a concentration of 0.1 - 0.2 µg/ml. Used in conjunction with compatible secondary reagents the detection limit for recombinant Human sTRAIL/Apo2L is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions. Note: 1mg will be provided as 2x500μg. crossreactivity: Human, Rat References SDS CoA Search Product Line Country Of Origin: USA Not for human use. Research Interest Apoptosis Cancer Immune System TNF Superfamily product.subtitle.recentcitations First Author Jeong, M Title Possible novel therapy for malignant gliomas with secretable trimeric TRAIL. Citation PLoS ONE; 4(2) pge4545 PubMed Id 19229339 First Author Mulherkar, N Title MADD/DENN splice variant of the IG20 gene is a negative regulator of caspase-8 activation. Knockdown enhances TRAIL-induced apoptosis of cancer cells. Citation The Journal of Biological Chemistry; 282(16) pg11715-21 PubMed Id 17314102 First Author Kim, C Title Cancer gene therapy using a novel secretable trimeric TRAIL. Citation Gene Therapy; 13(4) pg330-8 PubMed Id 16195699
